IS6009A - Lyfjablöndur sem samanstanda af (E)-7-[4-(4 flúorófenýl)-6-ísóprópýl-2-[metýl(metýlsúlfónýl) amínó]pýrimidín-5-ýl](3R,5S)-3,5-díhýdroxýhept-6-enósýruog lata, vaka eða hvarfefni af P450 ísóensími 3A4 - Google Patents
Lyfjablöndur sem samanstanda af (E)-7-[4-(4 flúorófenýl)-6-ísóprópýl-2-[metýl(metýlsúlfónýl) amínó]pýrimidín-5-ýl](3R,5S)-3,5-díhýdroxýhept-6-enósýruog lata, vaka eða hvarfefni af P450 ísóensími 3A4Info
- Publication number
- IS6009A IS6009A IS6009A IS6009A IS6009A IS 6009 A IS6009 A IS 6009A IS 6009 A IS6009 A IS 6009A IS 6009 A IS6009 A IS 6009A IS 6009 A IS6009 A IS 6009A
- Authority
- IS
- Iceland
- Prior art keywords
- dihydroxyhept
- isoenzyme
- lazy
- methylsulfonyl
- pyrimidin
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Transplantation (AREA)
- Urology & Nephrology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9902593.4A GB9902593D0 (en) | 1999-02-06 | 1999-02-06 | Drug combinations |
GBGB9921064.3A GB9921064D0 (en) | 1999-09-08 | 1999-09-08 | Drug combination |
GBGB9921063.5A GB9921063D0 (en) | 1999-09-08 | 1999-09-08 | Therapy |
PCT/GB2000/000278 WO2000045817A1 (en) | 1999-02-06 | 2000-02-01 | Drug combinations comprising (e) -7 - [4 -(4 -fluorophenyl) -6 - isopropyl -2 - [methyl (methylsulfonyl) amino] pyrimidin -5 -yl] (3r,5s) -3,5 - dihydroxyhept -6 - enoic acid and an inhibitor, inducer or substrate of p450 isoenzyme 3a4 |
Publications (2)
Publication Number | Publication Date |
---|---|
IS6009A true IS6009A (is) | 2001-07-17 |
IS2337B IS2337B (is) | 2008-02-15 |
Family
ID=27269637
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IS6009A IS2337B (is) | 1999-02-06 | 2001-07-17 | Lyfjasamsetning sem samanstendur af (E)-7-[4-(4 flúorófenýl)-6-ísóprópýl-2-[metýl(metýlsúlfónýl) amínó]pýrimidín-5-ýl](3R,5S)-3,5-díhýdroxýhept-6-enósýru og hindra, vaka eða hvarfefni af P450 samsætuensími 3A4 |
Country Status (29)
Country | Link |
---|---|
US (3) | US6982157B1 (is) |
EP (1) | EP1185274B1 (is) |
JP (2) | JP2002536331A (is) |
KR (2) | KR20010101790A (is) |
CN (1) | CN1165310C (is) |
AR (1) | AR029333A1 (is) |
AT (1) | ATE282415T1 (is) |
AU (1) | AU767304B2 (is) |
BR (1) | BR0007999A (is) |
CA (1) | CA2358632C (is) |
CZ (1) | CZ301296B6 (is) |
DE (1) | DE60015965T2 (is) |
EE (1) | EE04929B1 (is) |
EG (1) | EG23858A (is) |
ES (1) | ES2232418T3 (is) |
GB (1) | GB0000710D0 (is) |
HK (1) | HK1041817A1 (is) |
ID (1) | ID30485A (is) |
IL (1) | IL144715A0 (is) |
IS (1) | IS2337B (is) |
MX (1) | MXPA01007905A (is) |
MY (1) | MY130606A (is) |
NO (1) | NO320745B1 (is) |
NZ (1) | NZ512982A (is) |
PL (1) | PL198034B1 (is) |
PT (1) | PT1185274E (is) |
TR (1) | TR200102228T2 (is) |
TW (1) | TWI282738B (is) |
WO (1) | WO2000045817A1 (is) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5840737A (en) | 1996-01-04 | 1998-11-24 | The Curators Of The University Of Missouri | Omeprazole solution and method for using same |
US6489346B1 (en) | 1996-01-04 | 2002-12-03 | The Curators Of The University Of Missouri | Substituted benzimidazole dosage forms and method of using same |
DE19944803A1 (de) * | 1999-09-20 | 2001-03-29 | Bayer Ag | Kombination von Dihydropyridinverbindungen und HMG-CoA-Reduktase-Inhibitoren und ihre Verwendung in Arzneimitteln |
GB0001621D0 (en) * | 2000-01-26 | 2000-03-15 | Astrazeneca Ab | Pharmaceutical compositions |
GB0003305D0 (en) * | 2000-02-15 | 2000-04-05 | Zeneca Ltd | Pyrimidine derivatives |
US8993599B2 (en) | 2003-07-18 | 2015-03-31 | Santarus, Inc. | Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them |
GB0322552D0 (en) | 2003-09-26 | 2003-10-29 | Astrazeneca Uk Ltd | Therapeutic treatment |
KR20130103818A (ko) | 2003-10-10 | 2013-09-24 | 벨로시스 파마슈티컬스 에이/에스 | 피브레이트를 포함하는 고형 제제 |
US9173847B2 (en) | 2003-10-10 | 2015-11-03 | Veloxis Pharmaceuticals A/S | Tablet comprising a fibrate |
US8906940B2 (en) | 2004-05-25 | 2014-12-09 | Santarus, Inc. | Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them |
EP1786414A4 (en) | 2004-08-06 | 2008-04-09 | Transform Pharmaceuticals Inc | NEW PHARMACEUTICAL STATIN COMPOSITIONS AND RELEVANT TREATMENT PROCEDURES |
US20090162316A1 (en) | 2005-07-05 | 2009-06-25 | Harvard University | Liver targeted conjugates |
EP1968593B1 (en) * | 2005-12-20 | 2017-08-23 | LEK Pharmaceuticals d.d. | Pharmaceutical composition comprising (e)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl-(3r,5s)-3,5-dihydroxyhept-6-enoic acid |
US20080109252A1 (en) * | 2006-11-08 | 2008-05-08 | Lafountain Andrea | Predicting patient compliance with medical treatment |
US20120130202A1 (en) * | 2010-11-24 | 2012-05-24 | Fujitsu Limited | Diagnosis and Monitoring of Musculoskeletal Pathologies |
US11417416B2 (en) * | 2018-06-14 | 2022-08-16 | Astrazeneca Uk Limited | Methods for lowering blood pressure with a dihydropyridine-type calcium channel blocker pharmaceutical composition |
ES2931301T3 (es) | 2019-07-31 | 2022-12-28 | Intas Pharmaceuticals Ltd | Composición farmacéutica que comprende inhibidores de la HMG-CoA reductasa y fenofibrato |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2627696B1 (fr) * | 1988-02-26 | 1991-09-13 | Fournier Innovation Synergie | Nouvelle forme galenique du fenofibrate |
JP2648897B2 (ja) * | 1991-07-01 | 1997-09-03 | 塩野義製薬株式会社 | ピリミジン誘導体 |
ES2065113T3 (es) * | 1991-07-02 | 1995-02-01 | Benckiser Gmbh Joh A | Botella de almacenamiento plegable. |
JP3852621B2 (ja) * | 1992-01-21 | 2006-12-06 | あすか製薬株式会社 | 血管内皮細胞機能改善剤 |
FR2730231B1 (fr) * | 1995-02-02 | 1997-04-04 | Fournier Sca Lab | Association de fenofibrate et de vitamine e, utilisation en therapeutique |
AU1289899A (en) * | 1997-10-31 | 1999-05-24 | Arch Development Corporation | Methods and compositions for regulation of 5-alpha reductase activity |
-
2000
- 2000-01-14 GB GBGB0000710.4A patent/GB0000710D0/en not_active Ceased
- 2000-02-01 EE EEP200100406A patent/EE04929B1/xx unknown
- 2000-02-01 PL PL364780A patent/PL198034B1/pl unknown
- 2000-02-01 DE DE60015965T patent/DE60015965T2/de not_active Expired - Lifetime
- 2000-02-01 TR TR2001/02228T patent/TR200102228T2/xx unknown
- 2000-02-01 PT PT00901264T patent/PT1185274E/pt unknown
- 2000-02-01 CA CA002358632A patent/CA2358632C/en not_active Expired - Fee Related
- 2000-02-01 WO PCT/GB2000/000278 patent/WO2000045817A1/en not_active Application Discontinuation
- 2000-02-01 AT AT00901264T patent/ATE282415T1/de active
- 2000-02-01 ID IDW00200101892A patent/ID30485A/id unknown
- 2000-02-01 KR KR1020017009914A patent/KR20010101790A/ko active Search and Examination
- 2000-02-01 IL IL14471500A patent/IL144715A0/xx not_active IP Right Cessation
- 2000-02-01 KR KR1020067021986A patent/KR20060117381A/ko not_active Application Discontinuation
- 2000-02-01 NZ NZ512982A patent/NZ512982A/en not_active IP Right Cessation
- 2000-02-01 BR BR0007999-5A patent/BR0007999A/pt not_active Application Discontinuation
- 2000-02-01 CZ CZ20012844A patent/CZ301296B6/cs not_active IP Right Cessation
- 2000-02-01 MX MXPA01007905A patent/MXPA01007905A/es not_active IP Right Cessation
- 2000-02-01 CN CNB008034702A patent/CN1165310C/zh not_active Expired - Lifetime
- 2000-02-01 ES ES00901264T patent/ES2232418T3/es not_active Expired - Lifetime
- 2000-02-01 JP JP2000596937A patent/JP2002536331A/ja active Pending
- 2000-02-01 US US09/889,414 patent/US6982157B1/en not_active Expired - Lifetime
- 2000-02-01 EP EP00901264A patent/EP1185274B1/en not_active Expired - Lifetime
- 2000-02-01 AU AU21218/00A patent/AU767304B2/en not_active Expired
- 2000-02-04 MY MYPI20000416A patent/MY130606A/en unknown
- 2000-02-04 AR ARP000100507A patent/AR029333A1/es unknown
- 2000-02-22 EG EG20000124A patent/EG23858A/xx active
- 2000-05-11 TW TW089102105A patent/TWI282738B/zh not_active IP Right Cessation
-
2001
- 2001-07-17 IS IS6009A patent/IS2337B/is unknown
- 2001-08-03 NO NO20013811A patent/NO320745B1/no not_active IP Right Cessation
-
2002
- 2002-05-08 HK HK02103512A patent/HK1041817A1/xx unknown
-
2005
- 2005-03-15 US US11/079,530 patent/US20060040969A1/en not_active Abandoned
-
2007
- 2007-07-27 JP JP2007195798A patent/JP2007277267A/ja active Pending
-
2008
- 2008-09-29 US US12/285,117 patent/US20090042911A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IS8978A (is) | Samsettar samsetningar sem ná yfir (E)-7-[4-(4-flúorofenýl)-6-ísóprópyl-2-[metýl(metýlsúlfónýl)-amínó]pýrimídín-5-ýl](3R,5S)-3,5-díhýdroxýhept-6-enósýru | |
IS6009A (is) | Lyfjablöndur sem samanstanda af (E)-7-[4-(4 flúorófenýl)-6-ísóprópýl-2-[metýl(metýlsúlfónýl) amínó]pýrimidín-5-ýl](3R,5S)-3,5-díhýdroxýhept-6-enósýruog lata, vaka eða hvarfefni af P450 ísóensími 3A4 | |
DK1682536T3 (da) | Fremgangsmåde til fremstilling af calciumsaltet af rosuvastatin (e)-7-[4-(4-fluorphenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]-pyrimidin-5-yl](3r,5s)-3,5-dihydroxyhept-6-ensyre og krystallinske mellemprodukter deraf | |
ZA200205331B (en) | Crystalline salts of 7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl]-(3R,5S)-3,5-dihydroxyhept-6-enoic acid. | |
EE200100430A (et) | Tert-butüül-(E)-(6-[2-[4-(4-fluorofenüül)-6-isopropüül-2-[metüül(metüülsulfonüül)amino]pürimidiin-5-üül]vinüül](4R,6S)-2,2-dimetüül[1,3]dioksaan-4-üül)atsetaadi valmistamismeetod | |
CA2313783A1 (en) | Pharmaceutical compositions of (e)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl]-(3r,5s)-3,5-dihydroxyhept-6-enoic acid or a salt thereof | |
IL174073A0 (en) | Crystalline form of bis [(e) - 7 - [4 - (4 - fluorophenyl) - 6 - isopropyl - 2 - [methyl (methylsulphonyl) amino] pyrimidin - 5 - yl] (3r,5s) - 3,5 - dihydroxyhept - 6 - enoic acid] calcium salt | |
TWI341310B (en) | Improved production of (e)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3r,5s)-3,5-dihydroxyhept-6-enoic acid calcium salt | |
HUP0104828A2 (hu) | Kristályos bisz[ (E)-7-[4-(4-fluor-fenil)-6-izopropil-2-[metil-(metilszulfonil)-amino]-pirimidin-5-il]-(3R,5S)-3,5-dihidroxi-6-hepténsav]-kalciumsó, ezt tartalmazó készítmény és eljárás az előállításukra | |
CA2429263A1 (en) | Use of rosuvastatin (zd-4522) in the treatment of heterozygous familial hypercholesterolemia | |
HUP0104977A3 (en) | Drug combinations comprising (e)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl-(methylsulfonyl)-amino]pyrimidin-5-yl](3r,5s)-3,5-dihydroxyhept-6-enoic acid and an inhibitor, inducer or substrate of p450 isoenzyme 3a4 | |
SI1185274T1 (en) | Drug combinations comprising (e)-7-(4-(4-fluorophenyl)-6-isopropyl-2-(methyl(methylsulfonyl)amino)pyrimidin-5-yl)(3r,5s)-3,5-dihydroxyhept-6-enoic acid and an inhibitor, inducer or substrate of p450 isoenzyme 3a4 |